Slingshot members are tracking this event:

Portola Pharmaceuticals (NASDAQ: PTLA) receives Complete Response Letter (CRL) from FDA for BLA for Andexxa, an antidote for bleeding related to factor Xa inhibitors (8/17/2016).

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Management Comment Company receives acceptance of marketing authorization by EMA (Europe) for Andexxa 2 days after receiving CRL from FDA. 
Management Comment Press release regarding CRL by FDA is at following link.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Aug 17, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Factor Xa Inhibitor, Frequent Bleeding Episodes